Christopher Belcher
Pediatric Infectious Diseases · Carmel, INNPI 1407896392
Payments from drug & device makers
Across 762 payments — averaging $759.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi Pasteur Inc.$189K
- Merck$126K
- Parapro, LLC$104K
- Emergent Biosolutions Inc.$58K
- Sobi, Inc$57K
- Pfizer$44K
- plus $2K from 24 others
What the payments were for
- Consulting fees$15,5143%
- Speaking & faculty fees$474,72682%
- Travel & lodging$75,16313%
- Food & beverage$13,5742%
- Education$890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi Pasteur Inc. | 242 | $189,173 |
| Merck | 173 | $125,955 |
| Parapro, LLC | 6 | $103,615 |
| Emergent Biosolutions Inc. | 83 | $57,854 |
| Sobi, Inc | 146 | $57,373 |
| Pfizer | 47 | $43,561 |
| La Jolla Pharmaceutical Company | 3 | $348 |
| Paratek Pharmaceuticals, Inc. | 3 | $162 |
| AbbVie(2 entities) | 8 | $156 |
| Melinta Therapeutics, LLC | 7 | $109 |
| GSK | 3 | $75 |
| Valneva USA, Inc. | 4 | $62 |
| CSL Behring | 3 | $58 |
| Tetraphase Pharmaceuticals, Inc. | 3 | $55 |
| Astellas Pharma US Inc | 3 | $53 |
| Mayne Pharma Commercial LLC | 3 | $52 |
| Theratechnologies Inc. | 3 | $47 |
| Viiv Healthcare Company | 3 | $45 |
| Sanofi-aventis U.S. LLC | 1 | $41 |
| Johnson & Johnson | 2 | $41 |
| Napo Pharmaceuticals Inc | 3 | $34 |
| AstraZeneca | 2 | $34 |
| Amgen | 2 | $31 |
| Insmed, Inc. | 2 | $30 |
| Pharming Healthcare, Inc. | 1 | $26 |
| Tactile Systems Technology Inc | 2 | $26 |
| EMD Serono, Inc. | 1 | $14 |
| Gilead | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $11 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BEYFORTUS$103,570
- Natroba$82,988
- VAXNEUVANCE$65,929
- FLUZONE HIGH-DOSE$57,091
- Vaxchora$56,632
- Synagis$53,948
- ABRYSVO$40,394
- ENFLONSIA$34,007
- FLUBLOK QUADRIVALENT$30,737
- Vivotif$30,572
- Natroba Topical Suspension, 0.9%$20,627
- GARDASIL 9$14,520
- FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE$13,763
- GARDASIL$8,224
- MENQUADFI$7,923
- MENACYW CONJUGATE VACCINE$3,750
- PENTACEL$3,626
- PREVNAR 20$2,365
- FLUZONE QUADRIVALENT$880
- NO PRODUCT DISCUSSED$848
How this compares
Too few pediatric infectious diseases providers in Indianato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azithromycin | 22 | $66 |
Paid to pharmacies, not to this prescriber.
Other pediatric infectious diseases in Carmel
- Muayad AlaliIndianapolis$1K
- Robyn SchmuckerFort Wayne$1K
- Elaine CoxIndianapolis$200
- Lindsey KirkpatrickIndianapolis$75
- John ManaloorIndianapolis$69
- Douglas KelseyZionsville$40
- Benjamin WestonKokomo$29
- John ChristensonIndianapolis$12
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.